Evaluation of safety and therapeutic efficacy of siddha drug KANDAAMALAGA ILAKAM in the treatment of Iron deficiency anaemia.
Phase 2
- Conditions
- Health Condition 1: null- patients complaints with pallor of skin and mucus membrane, fatigue, lassitude,chest discomfort, breathlessness,pica,giddiness,dizziness,angular stomatitis, pungent or bitter taste.
- Registration Number
- CTRI/2018/05/014111
- Lead Sponsor
- Ayothidoss Pandithar Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Hb level less than normal range, For male:7-10gms/dl(normal:13-18gms/dl),For female:7-10gms/dl(normal:11.5-16.5), patient willing to undergo blood investigation, patient who are willing to participate in study and signing in informed consent form.
Exclusion Criteria
Hypertention, presence of any associated severe systemic illness (Eg.cancer, rheumatoid), Endocrine disorder( thyroid abnormality, diabetes mellitus), severe cardiac disease,Inherited defects(sickle cell Anemia, Thalassemia, Aplastic anaemia), patient not willing to give blood sample
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is mainly assessed by comparing the pre, mid and post treatment heamoglobin level of the study patient.Timepoint: 45 days
- Secondary Outcome Measures
Name Time Method secondary outcome is assessed by comparing the following parameters, before and after the treatment, Reduction of clinical symptoms, changes in complete blood count, changes in iron supply studies.Timepoint: 45 days